GLP-1s for Long COVID
GLP-1 drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound, are among the most talked-about medications of the past decade. That attention has spilled into the Long COVID world. The interest is not baseless: there are real biological reasons to study them. But the evidence for Long COVID specifically is still extremely thin.
Here is an honest look at what these drugs are, how people access them, and what we actually know.
A Brief History
GLP-1, or glucagon-like peptide-1, is a hormone made in the gut that helps regulate blood sugar, insulin release, digestion, and appetite. GLP-1 receptor agonists are drugs that mimic some of those effects.
The first GLP-1 receptor agonist, exenatide, was approved in 2005 for type 2 diabetes. Liraglutide followed, and then came semaglutide, sold as Ozempic and Rybelsus for diabetes and Wegovy for weight management. Tirzepatide, sold as Mounjaro and Zepbound, is a newer incretin drug that acts on two receptors, GIP and GLP-1. If you've used semaglutide (Ozempic, Wegovy) before, please consider adding a review to our database here. Or if you've used tirzepatide (Zepbound, Mounjaro), please consider adding a review to our database here.
What began as diabetes medicine became a major weight-loss phenomenon. More recently, these drugs have been studied for cardiovascular disease, sleep apnea, liver disease, kidney disease, inflammation, addiction, and other conditions well beyond blood sugar control.
Why People Are Looking at Them for Long COVID
The rationale is mechanistic, not proven.
GLP-1-based drugs do more than lower blood sugar and appetite. They can affect inflammation, vascular function, clotting-related pathways, weight, metabolic health, and cardiovascular risk. Because Long COVID may involve immune dysregulation, endothelial dysfunction, microvascular problems, and neuroinflammation in at least some patients, researchers have started asking whether these drugs could help.
One hypothesis behind brain-fog anecdotes is that reducing inflammation around small blood vessels could improve blood flow or vascular signaling. That is biologically plausible, but it has not been demonstrated as a Long COVID treatment mechanism.
It is also important to be precise about where the evidence is strongest. Much of the published COVID-related rationale involves people with obesity, type 2 diabetes, cardiovascular disease, or other metabolic risk factors. Those conditions increase the risk of severe COVID and may contribute to worse longer-term outcomes. That is a narrower claim than saying GLP-1 drugs treat Long COVID itself.
Getting Them: Who Prescribes Them, and How
GLP-1 drugs are prescription medications. They are most commonly prescribed by primary care doctors, endocrinologists, cardiologists, and obesity-medicine clinicians, usually for diabetes, weight management, or other approved indications. Prescribing them specifically for Long COVID is off-label and still uncommon.
Access has also changed. During the shortage years, some patients obtained compounded semaglutide or tirzepatide. But the FDA later determined that the tirzepatide shortage was resolved in late 2024 and the semaglutide injection shortage was resolved in February 2025. As of April 2026, FDA stated that semaglutide and tirzepatide were not on the drug shortage list. That removed the main legal basis for large-scale copycat compounding, though narrow individualized compounding exceptions may still exist.
In practice, many patients now face the brand-name products, high cash prices, and insurance rules that usually require an approved diagnosis such as type 2 diabetes, obesity, overweight with a weight-related condition, or another labeled indication. The “microdoses” discussed in some chronic-illness communities are also not how most branded injector products are designed or labeled to be used.
Reported and Possible Benefits
For diabetes, obesity, and cardiovascular risk reduction in selected patients, the benefits of GLP-1-based drugs are well established.
For Long COVID, the evidence is anecdotal. Some patients report improvements in fatigue, brain fog, inflammation-like symptoms, or exertional tolerance. Others report no benefit or worsening side effects. There is no confirmed Long COVID benefit yet.
It is also possible that some improvement in metabolically ill patients comes from treating obesity, insulin resistance, blood sugar instability, sleep apnea, or cardiovascular risk rather than from treating Long COVID directly.
Side Effects and Safety
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, reflux, abdominal pain, and reduced appetite. These are often worst when starting or increasing the dose.
More serious concerns include severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease, pancreatitis, and delayed stomach emptying. These drugs are not recommended for people with severe gastroparesis. They can also complicate anesthesia or procedures because delayed gastric emptying may increase aspiration risk.
There is a boxed warning about thyroid C-cell tumors based on animal data. These drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
One caution matters especially for the Long COVID and ME/CFS community. These are powerful appetite-suppressing and weight-reducing medications. Many people with Long COVID are not overweight; some are underweight or already losing weight because of illness. For them, unintended weight loss and lean-mass loss could be harmful. Patients with dysautonomia may also already have sluggish digestion, nausea, reflux, or constipation, which GLP-1 drugs can worsen.
This is not a casual “why not try it” medication. It is something to discuss carefully with a clinician who understands your medical history, weight trajectory, nutrition status, gastrointestinal symptoms, and other medications.
What the Research Actually Says
As of late May 2026, there are no published randomized trial results showing that GLP-1-based drugs treat Long COVID. No GLP-1 medication is approved or indicated for Long COVID.
The supporting evidence comes from adjacent areas. In the SELECT trial, semaglutide was associated with fewer COVID-related adverse events and deaths among people with overweight or obesity and established cardiovascular disease, but that study did not test Long COVID treatment. A large 2025 Veterans Affairs study using records from people with type 2 diabetes found broad associations between GLP-1 drugs and lower risk of some health outcomes, along with higher risk of others, but it was observational and not a Long COVID study.
The Long COVID-specific research is now beginning. Scripps Research has enrolled 1,000 participants in a remote randomized placebo-controlled trial of tirzepatide for Long COVID, with estimated completion in December 2026. RECOVER-TLC is also developing a GLP-1 trial for Long COVID, with enrollment estimated to begin in late summer 2026. Separately, researchers in Germany are planning a small observational semaglutide study in ME/CFS patients who are also being treated for excess weight.
Until those studies report, the fair summary is this: GLP-1-based drugs are a scientifically interesting candidate for Long COVID, especially in patients who already have a metabolic or cardiovascular reason to take them. But they are not an evidence-based Long COVID treatment yet, and they may be risky for people who are underweight, losing weight, or prone to severe gastrointestinal or autonomic symptoms.
If you'd like to find a provider who prescribes GLP-1s for Long COVID, search our database here.